<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="14873">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01800708</url>
  </required_header>
  <id_info>
    <org_study_id>1</org_study_id>
    <nct_id>NCT01800708</nct_id>
  </id_info>
  <brief_title>Cataract Surgery With Intracameral Triamcinolone in Infants</brief_title>
  <official_title>The Use of Intraocular Triamcinolone in the Perioperative Period of Congenital Cataract Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundação Altino Ventura</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundação Altino Ventura</source>
  <oversight_info>
    <authority>Brazil: Ethics Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the present study is to investigate the outcomes of congenital cataract surgery
      when injecting intraoperative intracameral triamcinolone versus the postoperative use of
      oral prednisolone.

      This is a prospective, randomized clinical trial. Sixty children will be submitted to
      congenital cataract surgery younger than 2 years of age. They will be randomly divided in
      two groups. The study group will receive an intraoperative intracameral triamcinolone
      acetonide injection. The control group will receive prednisolone syrup postoperatively. The
      surgical outcomes will be assessed after one year.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Visual axis obscuration</measure>
    <time_frame>1 year after surgery</time_frame>
    <safety_issue>No</safety_issue>
    <description>Visual axis obscuration will be evaluated under sedation, with a dilated pupil. All patients will be classified by the principal investigator as having or not a significant visual axis obscuration, based on the red reflex.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Intraocular pressure</measure>
    <time_frame>1 year after surgery</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Cataract</condition>
  <arm_group>
    <arm_group_label>Triamcinolone acetonide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The study group will receive an intraoperative intracameral injection of triamcinolone acetonide</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prednisolone syrup</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The control group will receive prednisolone syrup postoperatively</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Triamcinolone acetonide</intervention_name>
    <arm_group_label>Triamcinolone acetonide</arm_group_label>
    <other_name>Triancinolona Ophthalmos</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisolone syrup</intervention_name>
    <arm_group_label>Prednisolone syrup</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients younger than 2 years of age

          -  Unilateral or bilateral congenital cataracts compromising the red reflex

        Exclusion Criteria:

          -  Corneal opacity

          -  Glaucoma

          -  Aniridia

          -  Subluxated cataract

          -  Traumatic cataract

          -  Complex microphthalmia

          -  Persistant hyperplastic primary vitreous

          -  Retinal detachment

          -  Patients with intraoperative complications, such as IOL implanted in the sulcus
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>6 Weeks</minimum_age>
    <maximum_age>2 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marcelo Ventura, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fundação Altino Ventura</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Altino Ventura Foundation</name>
      <address>
        <city>Recife</city>
        <state>Pernambuco</state>
        <zip>50070020</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <lastchanged_date>August 13, 2013</lastchanged_date>
  <firstreceived_date>February 25, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cataract</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Triamcinolone hexacetonide</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Triamcinolone</mesh_term>
    <mesh_term>Triamcinolone Acetonide</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
    <mesh_term>Triamcinolone diacetate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
